BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

逸達生物科技股份有限公司

 

Company Info

Name /Foresee Pharmaceuticals

Address /9F-2, No.19-3, Sanchong Rd., Nangang Dist., Taipei City 115, Taiwan

Website /http://www.foreseepharma.com/

Presenter

Name /

Title /

Email /ir@foreseepharma.com

Telephone /(Work) (02)7750-0188

Fax /(02)7750-0199

Mobile /

Company Type

Pharmaceutical

About the Company

Foresee is a Taiwan and U.S.-based biopharmaceutical company listed on the Taipei Exchange. Foresee’s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting disease areas with high unmet needs.

Brief Description of main products or services

Foresee's product portfolio includes late stage and early stage programs. CAMCEVI 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI 21 mg. Foresee is in clinical stage development of FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases. FP-025 is currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). Foresee is also developing FP-045, a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia, and FP-004, a novel, subcutaneously injectable product in development for the treatment of opioid use disorder and pain.

Contact Person

Name /An Chung

Email /an.chung@foreseepharma.com

Phone /(02)7750-0188